Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
30 juil. 2024 07h00 HE
|
Fractyl Health, Inc.
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
29 juil. 2024 07h02 HE
|
Ocugen
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
25 juil. 2024 06h30 HE
|
Ocugen
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering,...
Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Spherix Global Insights
24 juil. 2024 09h56 HE
|
Spherix Global Insights
EXTON, PA., June 20, 2024, July 24, 2024 (GLOBE NEWSWIRE) -- The American Society of Retinal Specialists (ASRS) annual meeting held last week in Stockholm, Sweden, showcased groundbreaking...
Gene Therapies For Cardiomyopathies Therapeutics Market Report 2024: Current Treatment Patterns, Clinical Assessment of Products, Pipeline Development Activities
18 juil. 2024 07h16 HE
|
Research and Markets
Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "Gene Therapies For Cardiomyopathies - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.Gene Therapies For...
Gene Therapy Agreements Analysis Report and Directory 2024: Comprehensive Listing of 740 Deals Announced Since 2016
17 juil. 2024 05h31 HE
|
Research and Markets
Dublin, July 17, 2024 (GLOBE NEWSWIRE) -- The "Gene Therapy Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Gene Therapy Collaboration and...
California Institute for Regenerative Medicine (CIRM) Appoints New CEO
10 juil. 2024 15h30 HE
|
California Institute for Regenerative Medicine (CIRM)
South San Francisco, California, July 10, 2024 (GLOBE NEWSWIRE) -- The Independent Citizens’ Oversight Committee (ICOC), the governing board of the California Institute for Regenerative Medicine...
Neha Motwani Elected to Longeveron® Board of Directors
09 juil. 2024 09h00 HE
|
Longeveron
Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
09 juil. 2024 07h05 HE
|
uniQure Inc.
~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the...
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
08 juil. 2024 09h00 HE
|
Longeveron
Gene therapy pioneer Dr. Roger Hajjar elected to Longeveron Board of Directors as company advances it novel cellular therapy across multiple indications.